March 22, 2021 – Medtronic plc (Dublin, Ireland) announced it received CE Mark for the SenSight directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy.
The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved Percept PC neurostimulator. This system will enhance detection of local field potentials (LFPs) and offers directional stimulation to provide individualized and patient-specific data plus additional programming features to tailor therapy for patients.
With collaboration and insights from clinicians, Medtronic engineers have designed every component of the SenSight system to meet customer and patient needs and work seamlessly with the Percept PC neurostimulator to enhance detection of local field potentials (LFPs), which are 1 million times smaller than DBS stimulation pulses.
The product is currently under review by the U.S. Food and Drug Administration.